)
)
Company research3 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
BioNTech
BioNTech (BNTX) investor relations material
BioNTech Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
2026 strategic progress centered on late-stage oncology, tumor-focused development and combination therapies; six Phase III trials initiated during the year.
Pipeline and partnership breadth, alongside €16.2B in cash equivalents and security investments, support the ambition to become a diversified multi-product business by 2030.
Financial highlights
Q3 2026 revenue was €1,289.2M versus €1,518.9M YoY, primarily reflecting lower COVID-19 vaccine demand; €613M came from the BMS pumitamig partnership.
Q3 IFRS operating profit was €125.0M versus a €46.9M loss; IFRS net profit was €184.5M and adjusted net profit €440.9M.
9M 2026 revenue was €1,512.9M versus €1,962.5M; adjusted net loss was €615.9M versus €27.1M.
Q3 adjusted R&D was €578.5M versus €479M; IFRS R&D was €748.1M, including €169.6M in impairment adjustments. Q3 SG&A was €178.5M versus €148.5M.
9M adjusted R&D was €1,583M versus €1,514M; SG&A was €527.1M versus €406.5M.
Outlook and guidance
FY 2026 revenue guidance increased to €1.7B–€1.9B from €1.6B–€1.9B; adjusted R&D guidance is €2.0B–€2.3B and adjusted SG&A guidance €700M–€800M.
Seven global pivotal pumitamig studies are expected to be ongoing by year-end; event-driven trial timing and completion dates may change as data mature.
Gotistobart’s first pivotal-trial interim analysis is expected in 2026, subject to event accrual projections and IDMC review; a second analysis is planned next year.
First pivotal pumitamig combinations informed by signal-seeking data are expected to begin in 2027; 2027 financial plans remain in development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BioNTech
- Q2 2026 saw lower revenues, a widened net loss, pipeline progress, and robust liquidity.BNTX
Q2 2026 - All management proposals passed, with strategic focus shifting to oncology and major leadership changes.BNTXAGM 2026
- Oncology pipeline advances and cost savings offset lower COVID-19 vaccine sales and higher losses.BNTXQ1 2026
- Late-stage oncology pipeline accelerates with pivotal 2026 data and strong financials.BNTX44th Annual J.P. Morgan Healthcare Conference
- Late-stage oncology pipeline and partnerships drive growth, with key data expected in 2025–2026.BNTXR&D Day
- Q3 2025 revenues rose, net loss recorded, oncology and vaccine progress, guidance raised.BNTXQ3 2025
- AI-driven genomics and protein models deliver state-of-the-art advances in personalized immunotherapy.BNTXAI Day 2025
- AI-powered supercomputing and generative models are transforming immunotherapy and R&D workflows.BNTXAI Day 2024
- Q3 2024 revenues surged on early COVID-19 vaccine launches and oncology pipeline advances.BNTXQ3 2024
Next BioNTech earnings date
Q4 20262 Mar, 2027
BioNTech
Next BioNTech earnings date
Q4 20262 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Additionaly its clinical development will target the treatment of infectious diseases, including prophylactic vaccine approach that includes mRNA. It is also developing various neoantigen-based immunotherapies in collaboration with Pfizer Inc.; other checkpoint molecules; and next-generation antigen receptor T-cell products. The company was formerly known as BioNtech Therapeutics GmbH. BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.